Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3Other hematologic neoplasm 2Myeloid 2Lymphoid 2Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Sarcoma 5Leukemia, Myeloid, Acute 3Osteosarcoma 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia 2Hematologic Neoplasms 2Dendritic Cell Sarcoma, Interdigitating 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma, Myeloid 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Hodgkin Disease 1

Interventions

pembrolizumab 11Gemcitabine 10Doxorubicin 10Cyclophosphamide 9Specimen Handling 8Nivolumab 8Ibandronic Acid 8pazopanib 7Radiosurgery 6Magnetic Resonance Spectroscopy 6Imatinib Mesylate 6Biopsy 6Bevacizumab 6Irinotecan 5regorafenib 4Zoledronic Acid 4Ipilimumab 4Ifosfamide 4Fluorouracil 4Docetaxel 4Cetuximab 4sargramostim 3conatumumab 3cemiplimab 3Sunitinib 3Radiation 3Paclitaxel 3Leucovorin 3Cryosurgery 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Azacitidine × Sarcoma × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡